vTv Therapeutics (VTVT) Common Equity (2014 - 2026)

vTv Therapeutics has disclosed Common Equity across 13 years of filings, most recently posting $90.0 million for Q1 2026.

• Common Equity for Q1 2026 came in at $90.0 million, up 911.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.0 million (up 911.12% YoY), and the FY2025 annual result was $64.4 million, up 428.22% from the prior year.
• Common Equity came in at $90.0 million for Q1 2026 at vTv Therapeutics, up from $64.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.0 million in Q1 2026 to a low of -$25.3 million in Q2 2023.
• The 5-year median for Common Equity is $2.4 million (2025), against an average of $10.3 million.
• Across the five-year window, Common Equity sank 196.54% in 2023 and jumped 911.12% in 2026, its largest moves.
• vTv Therapeutics' Common Equity stood at -$10.7 million in 2022, then sank by 129.8% to -$24.7 million in 2023, then jumped by 149.43% to $12.2 million in 2024, then surged by 428.22% to $64.4 million in 2025, then jumped by 39.61% to $90.0 million in 2026.
• The last three Common Equity figures came in at $90.0 million (Q1 2026), $64.4 million (Q4 2025), and $70.5 million (Q3 2025), per Business Quant data.